Optimized Phase III Trial of Immuno-stimulation With Maraviroc, a CCR5 (Chemokine Receptor 5) Antagonist, Combined With Anti Retroviral Therapy in Advanced, Late Diagnosed HIV-1 Infected Patients With an AIDS-defining Event and/or CD4 (Cluster of Differentiation 4) Counts Below 200 Cells/mm³. ANRS 146 OPTIMAL.

Trial Profile

Optimized Phase III Trial of Immuno-stimulation With Maraviroc, a CCR5 (Chemokine Receptor 5) Antagonist, Combined With Anti Retroviral Therapy in Advanced, Late Diagnosed HIV-1 Infected Patients With an AIDS-defining Event and/or CD4 (Cluster of Differentiation 4) Counts Below 200 Cells/mm³. ANRS 146 OPTIMAL.

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Jul 2017

At a glance

  • Drugs Maraviroc (Primary) ; Efavirenz; Fosamprenavir; Ritonavir
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms OPTIMAL
  • Most Recent Events

    • 26 Jul 2017 Primary endpoint [The clinical benefit is the reduction of occurence of a composite outcome consisting of: New AID-defining event (1993 CDC(Centers for Disease Control) expanded surveillance definition)] has not been met, according to results presented at the 9th International AIDS Society Conference on HIV Science.
    • 26 Jul 2017 Results assessing clinical benefit of the adjunction of Maraviroc in combination with antiretroviral therapy in naive and late diagnosed HIV-1 infected patients presented at the 9th International AIDS Society Conference on HIV Science.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top